Company intelligence / Profile preview

Sanochemia Pharmazeutika

Neufeld an der Leitha, Burgenland, Austria

Ownership: Private
Employees: ~130
Development stage: Other

Overview

Sanochemia has reached pivotal late Phase III for Ferrotran® (ferumoxtran) MRI contrast agent for detection of lymph node metastases in prostate cancer, with deployment in named-patient-use programs (>700 patients diagnosed). Its legacy APIs (e.g., galantamine hydrobromide for Alzheimer’s) are commercialized, and it operates as a CDMO for sterile injectables and small molecule APIs.

Therapeutic areas: OncologyNeurologyOther
Modalities: Small moleculeNanoparticleBiologic (as APIs manufactured for clients)
Industry: Biotech

Partnerships

SPL Medical (licensing for Ferrotran® MRI agent)b.e.imaging (development/distribution agreement for Resotran® MRI agent)

Beyond the preview

Go deeper on Sanochemia Pharmazeutika.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanochemia Pharmazeutika.

Explore the full profile